PACTR202307901658960Not yet recruitingPhase 1
A Phase 1b, Multicenter, Randomized, Placebo-controlled, Observer-blinded, Dose-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar.
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Not yet recruiting
- Enrollment
- 120
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 19 Year(s) to 44 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •1. Healthy male or female participants aged 20 to 59 years at the time of consent.
- •2. Participant who has completed the deworming using praziquantel (PZQ) and albendazole (ABZ) according to local guidelines, with the last dose of PZQ/ABZ administered at least 5 weeks prior to first dose of study product.
- •3. Participant who, after the nature of the study has been explained, has voluntarily given informed consent, according to the local regulatory requirements, prior to study entry.
- •4. Participant who can comply with the study procedures and available for the entire duration of the study (32 weeks).
- •5. Individuals in good health as determined by the outcome of medical history, physical examination, hematology and biochemistry tests at the time of screening and the clinical judgment of the investigator.
- •6. Women of childbearing potential* with negative urinary test result on a human chorionic gonadotropin pregnancy test on the day of randomization, before receiving any study product.
- •7. Males or females of childbearing potential who are using an effective birth control method recommended by the national health system for at least four (4) weeks before the first vaccination (for female participants only) and up to four (4) weeks after the third vaccination (i.e., for at least 4 months).
Exclusion Criteria
- •1. Participant with major congenital abnormalities which in the opinion of investigator may affect the subject’s participation in the study.
- •2. Participant concomitantly enrolled or scheduled to be enrolled in another trial.
- •3. Positive rapid test for HIV 1-2 confirmed by a positive blood test for human immunodeficiency virus (positive antibodies to HIV 1/2).
- •4. Participant seropositive for hepatitis B virus surface antigen (HBsAg).
- •5. Participant seropositive for hepatitis C virus (Antibodies to HCV).
- •6. Participant with active or chronic Schistosomiasis infection defined by a positive result for microscopy (Urine filtration, Kato-Katz (KK)) and point-of-care – circulating cathodic antigen (POC –CCA) and/or real-time PCR.
- •7. Participant with soiled transmitted helminths infections (STH) as diagnosed by microscopy (KK) and/or real-time PCR.
- •8. Participant with malaria infection/malaria as diagnosed by the blood smear.
- •9. Any other confirmed or suspected immunosuppressive or immunodeficient state such as asplenia, recurrent severe infections.
- •10. Body mass index (BMI) = 35 kg/m2
- •11. Chronic use of systemic steroids (>2 mg/kg/day or >20 mg/day prednisolone equivalent for periods exceeding 10 days), cytotoxic or other immunosuppressive drugs.
- •12. Receipt of blood or blood-derived products in the past 3 months.
- •13. Participant who has received other vaccines 4 weeks prior to test vaccination or plans to receive any vaccine within 4 weeks of last dose of study vaccine, exception made for COVID-19 vaccines.
- •14. Known history of allergy to study vaccine components and/or excipients or other medications, or any other allergies deemed by the investigator to increase the risk of an adverse event if they were to participate in the trial.
- •15. Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time resulting in contraindication for IM injections/blood extractions.
Investigators
Similar Trials
Recruiting
Not Applicable
A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study, followed by an Open-Label Extension, to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants with Amyotrophic Lateral SclerosisNL-OMON56265Denali Therapeutics Inc15
Active, not recruiting
Phase 1
A Study of LY3844583 in Healthy Participants and Participants With Atopic DermatitisJPRN-jRCT2031220745Wakayama Naohiko86
Active, not recruiting
Phase 1
A Phase 2a, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Interventional Study to Assess the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Multiple IV doses of Bermekimab for the Treatment of Adult Participants with Moderate-to-Severe Atopic DermatitisModerate to Severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2020-005900-21-DEJanssen-Cilag International NV60
Active, not recruiting
Not Applicable
For Treatment Augmentation in Patients with Major Depressive Disorder.depressionEUCTR2011-005200-15-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.326
Active, not recruiting
Not Applicable
For Treatment Augmentation in Patients with Major Depressive Disorder.depressionEUCTR2011-005200-15-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.326